Login to Your Account



Flamel, BMS Enter Insulin Deal With Potential Value Of $165M

By James Etheridge


Wednesday, September 3, 2003
PARIS - Flamel Technologies SA and Bristol-Myers Squibb Co. signed a licensing and commercialization agreement covering Flamel's human insulin product, Basulin. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription